{"disease":{"id":"hereditary-spastic-paraplegia-type-5","name":"hereditary spastic paraplegia type 5"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04101643","title":"PCSK9 Inhibitor Treatment for Patients With SPG5","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT06692712","title":"Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Elpida Therapeutics SPC","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}